EBV INTERNAL REPEAT TRANSCRIPTION UNIT IN LATENCY

爱泼斯坦-巴尔病毒与伯基特淋巴瘤有关， 未分化的鼻咽癌，以及一些 淋巴增生性疾病。在体外，病毒可以将B细胞转化为 淋巴细胞转化为含有异构体的永生淋巴母细胞系 病毒基因组，并沿着病毒基因的子集表达。基因组由 唯一的短(12kb)和长(124kb)区域由一个大的30kb分隔 3.1kb序列的串联重复分析(IR1)。IR1是主要的体格检查 基因组的特征，在潜伏期转录，编码其中一个 潜伏的核抗原(EBNA4，也称为EBNA-LP)和贡献 所有EBNA的mRNAs的先导外显子。复杂的拼接模式 在最初感染时，潜伏转录通过IR1，在潜伏期间 在诱导病毒产生后，潜伏期将是 通过直接Northern印迹和 跨越剪接接头的寡核苷酸与聚合酶链式反应 利用互补的特异性引物扩增mRNAs片段 拼接接头和外显子，以及3‘和5’锚定的非特异性引物。 由于只需要少量的初始材料进行聚合酶链式反应，因此 将开发直接检查组织活检的技术。这个 通过添加加工在体外剖析其调节机制 底物。所获得的信息将广泛地映射IR1 转录单位，开发体外模型来检查IR1的调控 转录处理，并确定IR1对原位的贡献 潜伏期和淋巴肿大。开发的技术和试剂将是 对进一步的研究很有用，也可能对 EB病毒相关性淋巴增生性疾病的发病机制研究 和肿瘤。

The Epstein-Barr virus is associated with Burkitt's lymphoma, undifferentiated nasopharyngeal carcinoma, and a number of lymphoproliferative disorders. In vitro the virus can convert B lymphocytes into immortal lymphoblastoid cell lines which contain episomal viral genomes and express along subset of viral genes. The genome consists of unique short (12kb) and long (124kb) regions separated by a large 30kb tandem repeat assay (IR1) of a 3.1kb sequence. IR1 is the major physical feature of the genome, is transcribed during latency, encodes one of the latent nuclear antigens (EBNA4, also termed the EBNA-LP) and contributes leader exons to the mRNAs of all the EBNAs. The complex splicing pattern of latent transcripts through IR1 upon initial infection, during latency and after induction of virus production from a latent state will be investigated by a combination of direct Northern blotting with olignucleotides spanning splice junctions and polymerase chain reaction amplification of mRNA fragments using specific primers complementary to splice junctions and exons, and non-specific primers for 3' and 5' anchors. Since only small amounts of initial material are necessary for PCR, this technique will be developed for direct examination of tissue biopsies. The mechanism of regulation will be dissected in vitro by adding processing substrates. The information obtained will extensively map the IR1 transcription unit, develop in vitro models for examining control of IR1 transcript processing, and define the contribution of IR1 to in situ latency and lymphomagenesis. The techniques and reagents developed will be useful in further studies and may also be of diagnostic utility in assessing the pathogenesis of EBV associated lymphoproliferative disorders and neoplasms.